Medincell

Christophe Douat, Richard Malamut and Grace Kim will participate at the following conferences in December: 8th Annual Evercore Healthcare Conference (Miami, Dec. 2-4) 📌 Fireside chat on Wednesday, December 3, 2025, at 9:35am ET (3:35pm CET) 🔗 Live webcast and replay: https://lnkd.in/eRkCZY_3   Piper Sandler 37th Annual Healthcare Conference (New-York, Dec. 2-4) 📌 Fireside chat on Thursday, December 4, 2025, at 11:00am ET (5:00pm CET) 💬 Meetings can be arranged directly with Medincell or through banking representatives.

Medincell will benefit from a grant of up to $3 million awarded by the Gates Foundation to advance the mdc-STM malaria program, an investigational, three-month, subcutaneous injectable formulation of ivermectin, designed to eliminate malaria-transmitting mosquitoes when they bite treated individuals. According to the World Health Organization, malaria infected approximately 263 million people worldwide in 2023, with 94% of cases occurring in Africa and resulting in about 597,000 deaths, the vast majority among children under the age of five. Press release: https://lnkd.in/etdJnggB #malaria #globalhealth

Christophe Douat, CEO, will join Dr. Richard Malamut (Chief Medical Officer), Dr. Grace Kim (Chief Strategy Officer, U.S. Finance), and Sebastien Enault (Chief Business Officer) at the Jefferies London Healthcare Conference, taking place in London from November 17–20, 2025. 📌 Fireside Chat November 18 at 5:00 PM CET / 4:00 PM GMT / 11:00 AM ET 🔗 Live webcast & replay: https://lnkd.in/ep-FEFnV 💬 Meetings can be arranged directly with Medincell or through banking representatives.

🇺🇸 UZEDY® has received U.S. FDA approval for the treatment of adults living with Bipolar I Disorder. Read the press release: https://lnkd.in/efMGyKZp   Medincell's long-acting risperidone formulation is now positioned to help address critical unmet needs and treatment gaps for individuals affected by Bipolar I Disorder.   Since its U.S. launch by our partner Teva Pharmaceuticals, UZEDY has shown strong momentum. This new approval will reinforce its value to patients, caregivers, and healthcare providers.

🇨🇦 LONGAVO® - Long-Acting Injectable Risperidone - approved in Canada for the treatment of schizophrenia in adults Congrats to our partner Teva Pharmaceuticals! Press release: https://lnkd.in/ewR9BTjx

Our partner Teva Pharmaceuticals to Host Investor Call on Olanzapine LAI Phase 3 Data Following its presentation at Psych Congress 2025, Teva will hold a conference call on Sept 22 at 11:00 am ET to discuss results from the SOLARIS trial of Olanzapine LAI, a once-monthly, long-acting injectable for schizophrenia using Medincell’s technology. 🔗 Join the webcast: https://lnkd.in/evADm288 #Medincell #Teva #OlanzapineLAI #PsychCongress2025 #Schizophrenia #SteadyTeq #SOLARIStrial #UZEDY #InvestorRelations

We are proud to welcome Dr. Sharon Mates, Ph.D., Dr. Charles Kunsch, and Dr. Pascal Touchon to Medincell’s Board of Directors. "Their arrival brings a wealth of experience in innovation, strategic vision, and influential networks. Their contributions will be instrumental in shaping Medincell’s future - reinforcing our leadership, expanding our impact, and creating lasting value," said Philippe Guy, Chairman of the Board. Dr. Sharon Mates, PhD – Co-founder and former Chair & CEO of Intra-Cellular Therapies, a CNS-focused biotech behind the successful drug CAPLYTA®, acquired by Johnson & Johnson for $14.6 billion in April 2025. Dr. Charles Kunsch, PhD – A seasoned life sciences executive with over 30 years of experience, including as former Managing Director at AbbVie Ventures, where he led investments in breakthrough biotech companies. Dr. Pascal Touchon, DVM – Brings over 40 years of international leadership in biopharma, with key roles at Novartis Oncology and Atara Biotherapeutics, current board positions at Ipsen, CDR-Life Inc., RoslinCT, CatalYm GmbH, XyloCor Therapeutics, Inc., and serves as Operating Partner at JEITO Capital. Press release: https://lnkd.in/eYhMXZUN

🇰🇷 UZEDY® approved in South Korea Congrats to our partner Teva Pharmaceuticals! Following its successful U.S. launch, UZEDY® continues to build momentum, with $117M in net sales in 2024 and already $95M in H1 2025. Medincell earns mid- to high-single digit royalties on global sales and remains eligible for up to $105M in commercial milestones. Press release: https://lnkd.in/ed4DHkJb 🇰🇷 #Medincell #UZEDY #Teva #Schizophrenia #Innovation #LongActingInjectables #GlobalHealth

Christophe Douat, Chief Executive Officer, will participate along with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, in the following September New York conferences: H.C. Wainwright & Co., LLC 27th Annual Global Investment Conference, September 8 - 10, 2025 > Presentation on September 10 at 12:00pm > Live webcast and replay: https://lnkd.in/eRQs26xM Morgan Stanley 23rd Annual Global Healthcare Conference, September 8 - 10, 2025 Meetings may be requested via direct contact with Medincell or via banking representatives.

I’ll be attending the 34th Annual Conference of the European Society for Biomaterials in Torino starting 8th September. Looking forward to discovering new cutting-edge tools for drug delivery and to reconnecting with the world of Biomaterials, my academic home. If you’re attending too and would like to explore how BEPO, our technology, can enable superior drug delivery systems, feel free to reach out! #Medincell #BetterMedicineForAll #ESB2025 https://esb2025.org/#